Literature DB >> 24125562

Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

V Isella, C Mapelli, N Morielli, D De Gaspari, C Siri, G Pezzoli, A Antonini, M Poletti, U Bonuccelli, L Picchi, A Napolitano, M Vista, M Veglia, F Piamarta, F Grassi, I M Appollonio.   

Abstract

The Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog) has been shown to be a clinimetrically rigorous and valid instrument for a disease-oriented neuropsychological assessment of Parkinson's disease (PD) patients. In the present study we evaluated the psychometric properties of the Italian version of the SCOPA-Cog in 121 PD patients. The scale explores memory, attention, and executive and visuospatial functions and takes approximately 20 minutes to administer. Data distribution (skewness= -0.23) and internal consistency (Cronbach's alpha= 0.78) were satisfactory. Standard error of measurement was 3.42. The outcome was significantly worse in patients with an abnormal Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog) score on the Dementia Rating Scale (DRS) (SCOPACog mean score 14.6 ± 5.1 out of a total of 43) with respect to cognitively intact subjects (24.2 ± 4.3) (p<0.0001). The DRS showed good convergent validity (Spearman rho= 0.77, p<0.0001), and a high coefficient of variation (= 0.34). These findings support the goodness of the Italian SCOPA-Cog in terms of metrics and validity.

Entities:  

Mesh:

Year:  2013        PMID: 24125562      PMCID: PMC3812729          DOI: 10.11138/FNeur/2013.28.2.121

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  17 in total

Review 1.  Assessing health status and quality-of-life instruments: attributes and review criteria.

Authors:  Neil Aaronson; Jordi Alonso; Audrey Burnam; Kathleen N Lohr; Donald L Patrick; Edward Perrin; Ruth E Stein
Journal:  Qual Life Res       Date:  2002-05       Impact factor: 4.147

2.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

3.  Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.

Authors:  F A H van der Linden; J J Kragt; M Klein; H M van der Ploeg; C H Polman; B M J Uitdehaag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

4.  Mini-Mental Parkinson: first validation study of a new bedside test constructed for Parkinson's disease.

Authors:  F Mahieux; D Michelet; M J Manifacier; F Boller; J Fermanian; A Guillard
Journal:  Behav Neurol       Date:  1995       Impact factor: 3.342

5.  SCOPA-cognition cutoff value for detection of Parkinson's disease dementia.

Authors:  Dagmar Verbaan; Martine Jeukens-Visser; Teus Van Laar; Stephanie M van Rooden; Erik W Van Zwet; Johan Marinus; Jacobus J van Hilten
Journal:  Mov Disord       Date:  2011-05-03       Impact factor: 10.338

6.  Metric properties of the mini-mental Parkinson and SCOPA-COG scales for rating cognitive deterioration in Parkinson's disease.

Authors:  Marcos Serrano-Dueñas; Belén Calero; Soledad Serrano; Maite Serrano; Paulina Coronel
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

7.  The MoCA: well-suited screen for cognitive impairment in Parkinson disease.

Authors:  J C Dalrymple-Alford; M R MacAskill; C T Nakas; L Livingston; C Graham; G P Crucian; T R Melzer; J Kirwan; R Keenan; S Wells; R J Porter; R Watts; T J Anderson
Journal:  Neurology       Date:  2010-11-09       Impact factor: 9.910

8.  The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia.

Authors:  Donna L Lamping; Sara Schroter; Patrick Marquis; Alexia Marrel; Isabelle Duprat-Lomon; Pierre-Philippe Sagnier
Journal:  Chest       Date:  2002-09       Impact factor: 9.410

Review 9.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

10.  Cognitive impairment in Parkinson's disease.

Authors:  D Verbaan; J Marinus; M Visser; S M van Rooden; A M Stiggelbout; H A M Middelkoop; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-18       Impact factor: 10.154

View more
  3 in total

Review 1.  Cognitive and behavioral disorders in Parkinson's disease: an update. I: cognitive impairments.

Authors:  Costanza Papagno; Luigi Trojano
Journal:  Neurol Sci       Date:  2017-10-17       Impact factor: 3.307

2.  Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Authors:  Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Codrin Lungu; F DuBois Bowman; Roy N Alcalay; Debra Babcock; Ted M Dawson; Richard B Dewey; Tatiana Foroud; Dwight German; Xuemei Huang; Vlad Petyuk; Judith A Potashkin; Rachel Saunders-Pullman; Margaret Sutherland; David R Walt; Andrew B West; Jing Zhang; Alice Chen-Plotkin; Clemens R Scherzer; David E Vaillancourt; Liana S Rosenthal
Journal:  Biomark Med       Date:  2017-06-23       Impact factor: 2.851

Review 3.  Psychometrics and diagnostics of Italian cognitive screening tests: a systematic review.

Authors:  Edoardo Nicolò Aiello; Sara Rimoldi; Nadia Bolognini; Ildebrando Appollonio; Giorgio Arcara
Journal:  Neurol Sci       Date:  2021-11-24       Impact factor: 3.830

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.